11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Gold sell
Period: 31.10.2026 Expectation: 4000 pips
Go short on gold with $4,300 in mind
Yesterday at 04:54 AM 18
Period: 31.10.2026 Expectation: 100 pips
Buy Brent crude upon breaking $104.60
Yesterday at 04:54 AM 18
Period: 02.11.2026 Expectation: 1700 pips
GBPUSD sell-off targets 1.3200
22 September 2026 35
Period: 31.10.2026 Expectation: 300 pips
Buying AUDCAD with 1.0000 in sight
21 September 2026 37
Period: 31.10.2026 Expectation: 700 pips
Invest in USDJPY up to 157.70
21 September 2026 33
Gold sell
Period: 31.10.2026 Expectation: 3000 pips
Gold sell-off targets $4,000
18 September 2026 56
Go to forecasts